Free Shipping on All Orders $75 Or More!

Your Trusted Brand for Over 35 Years

Health Protocols



  1. CDC. Centers for Disease Control and Prevention. Current Depression among Adults – united states, 2006 and 2008 Morbidity and Mortality weekly Report October 1, 2010 Erratum. Availble at: Accessed 10/31/2011.
  2. Andrews G et al. Lifetime risk of depression: restricted to a minority or waiting for most? Br J Psychiatry. 2005 Dec;187:495-6.
  3. Howland RH. Use of endocrine hormones for treating depression. J Psychosoc Nurs Ment Health Serv. 2010 Dec;48(12):13-6. doi: 10.3928/02793695-20101105-01. Epub 2010 Nov 22.
  4. ICSI. Institute for Clinical Systems Improvement. Health care Guideline: Major Depression in Adults in Primary Care. May 2011. Available at Accessed 11/2/2011.
  5. Prescrire Int. Treatment-resistant depression: no panacea, many uncertainties. Adverse effects are a major factor in treatment choice. Prescrire Int. 2011 May;20(116):128-33.
  6. Parker G et al. 'D' for depression: any role for vitamin D? 'Food for Thought' II. Acta Psychiatr Scand. 2011 Oct;124(4):243-9. doi: 10.1111/j.1600-0447.2011.01705.x. Epub 2011 Apr 12.
  7. Liu RT, Alloy LB. Stress generation in depression: a systematic review of the empirical literature and recommendations for future study. Clin Psychol Rev 2010a;30:582-93.
  8. Maes M et al. Activation of cell-mediated immunity in depression: Association with inflammation, melancholia, clinical staging and the fatigue and somatic symptom cluster of depression. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Sep 16. [Epub ahead of print]
  9. Wolkowitz OM, Reus VI, Mellon SH. Of sound mind and body: depression, disease, and accelerated aging. Dialogues Clin Neurosci 2011b;13:25-39.
  10. Joëls M. Impact of glucocorticoids on brain function: relevance for mood disorders. Psychoneuroendocrinology. 2011 Apr;36(3):406-14.
  11. van Riel E, Meijer OC, Steenbergen PJ, et al. Chronic unpredictable stress causes attenuation of serotonin responses in cornu ammonis 1 pyramidal neurons. Neuroscience. 2003;120(3):649-58.
  12. Karten YJ, Nair SM, van Essen L, et al. Long-term exposure to high corticosterone levels attenuates serotonin responses in rat hippocampal CA1 neurons. Proc Natl Acad Sci USA. 1999 Nov;96(23):13456-61.
  13. Anacker C, Zunszain PA, Carvalho LA, et al. The glucocorticoid receptor: pivot of depression and of antidepressant treatment? Psychoneuroendocrinology. 2011 Apr;36(3):415-25.
  14. Ströhle A, Holsboer F. Stress responsive neurohormones in depression and anxiety. Pharmacopsychiatry. 2003 Nov;36 Suppl 3:S207-14.
  15. Binder EB, Nemeroff CB. The CRF system, stress, depression and anxiety-insights from human genetic studies. Mol Psychiatry. 2010 Jun;15(6):574-88.
  16. Bennett AO MR. Stress and anxiety in schizophrenia and depression: glucocorticoids, corticotrophin-releasing hormone and synapse regression. Aust N Z J Psychiatry. 2008; 42(12):995-1002.
  17. McCown D, Reibel DK, Micozzi MS. Teaching mindfulness: a practical guide for clinicians and educators. Springer Science and Business Media, LLC, New York, 2010.
  18. Newberg AB. The neurobiology of meditation. In Monti DA, Beitman BD (eds), Integrative Psychiatry. Oxford, England: Oxford University Press, Inc., pp. 339-58, 2010.
  19. Katsamanis MK, Lehrer PM, et al. Preliminary results of an open label study of heart rate variability biofeedback for major depression. Appl Psychophys Biofeedback 2007;32:19-30.
  20. Dusek JA, Otu HH, Wohlhueter AL, et al. Genomic counter-stress changes induced by the relaxation response. PLoS One. 2008 Jul;3(7):e2576.
  21. Dusek JA et al. Mind-body medicine: a model of the comparative clinical impact of the acute stress and relaxation responses. Minn Med. 2009 May;92(5):47-50.
  22. Nemeroff CB. Improving antidepressant adherence. J Clin Psychiatry. 2003;64 Suppl 18:25–30.
  23. Grav S et al. Association between social support and depression in the general population: the HUNT study, a cross-sectional survey. J Clin Nurs. 2011 Oct 24. doi: 10.1111/j.1365-2702.2011.03868.x. [Epub ahead of print]
  24. Kiecolt-Glaser JK, Gouin JP, et al. Close relationships, inflammation and health. Neurosci Biobehav Rev 2010;35:33-8.
  25. Coughlin PA. Facilitating emotional health and well-being. In Monti DA, Beitman BD (eds), Integrative Psychiatry. Oxford, England: Oxford University Press, Inc., pp. 383-407, 2010.
  26. Yang YK, Yeh TL, Yao WJ et al. Greater availability of dopamine transporters in patients with major depression a dual isotope SPECT study. Psychiatry Res. 2008 162 (15):230-5.
  27. Joensuu M, Tomunen T, Saarinen PI et. al. Reduced midbrain serotonin transporter availability in drug-naïve patients with depression measured by SERT-specific [(123)I] nor beta CIT SPECT imaging. Psychiatry 2007 154 (2): 125-31
  28. Wolff LC et al. [Depression in HIV infection: prevalence, risk factors and management]. Rev Chilena Infectol. 2010 Feb;27(1):65-74. Epub 2010 Feb 3.
  29. Liu SS et al. Depression in patients with heart disease: the case for more trials. Future Cardiol. 2010b Jul;6(4):547-56.
  30. Morris R et al. Depression and anxiety screening after stroke: adherence to guidelines and future directions. Disabil Rehabil. 2011 Oct 17. [Epub ahead of print]
  31. Jayadevappa R et al. The burden of depression in prostate cancer. Psychooncology. 2011 Aug 12. doi: 10.1002/pon.2032. [Epub ahead of print]
  32. Stuart MJ et al. Depression and type 2 diabetes: Inflammatory mechanisms of a psychoneuroendocrine co-morbidity. Neurosci Biobehav Rev. 2011 Oct 14. [Epub ahead of print]
  33. Hemmerle AM et al. Stress, depression and Parkinson's disease. Exp Neurol. 2011 Oct 6. [Epub ahead of print]
  34. Shibasaki M et al. [Functional homology between alcohol dependence and mood disorder]. Nihon Arukoru Yakubutsu Igakkai Zasshi. 2011 Jun;46(3):337-46.
  35. Stipcevic T et al. Platelet serotonin concentration and monoamine oxidase activity in hypothyroid patients. Horm Res. 2009;71(4):207-12. Epub 2009 Mar 4.
  36. Davis JD et al. Neuropsychiatric aspects of hypothyroidism and treatment reversibility. Minerva Endocrinol. 2007 Mar;32(1):49-65.
  37. Chang KD et al. Differences in thyroid function between bipolar manic and mixed states. Biol Psychiatry. 1998 May 15;43(10):730-3.
  38. Kupka RW et al. High rate of autoimmune thyroiditis in bipolar disorder: lack of association with lithium exposure. Biol Psychiatry. 2002 Feb 15;51(4):305-11.
  39. Cole DP et al. Slower treatment response in bipolar depression predicted by lower pretreatment thyroid function. Am J Psychiatry. 2002 Jan;159(1):116-21.
  40. Frye MA et al. Association between lower serum free T4 and greater mood instability and depression in lithium-maintained bipolar patients. Am J Psychiatry. 1999 Dec;156(12):1909-14.
  41. Cunningham J, Yonkers KA, O'Brien S, Eriksson E. Update on research and treatment of premenstrual dysphoric disorder. Harv Rev Psychiatry. 2009;17(2):120-37.
  42. Parcells DA. Women's mental health nursing: depression, anxiety and stress during pregnancy.J Psychiatr Ment Health Nurs. 2010 Nov;17(9):813-20.
  43. Bloch M, Aharonov I, Ben Avi I, et al. Gonadal steroids and affective symptoms during in vitro fertilization: implication for reproductive mood disorders. Psychoneuroendocrinology. 2011 Jul;36(6):790-6.
  44. Sundermann EE, Maki PM, Bishop JR.A review of estrogen receptor alpha gene (ESR1) polymorphisms, mood, and cognition. Menopause. 2010 Jul;17(4):874-86.
  45. Kikuchi H, Nakatani Y, Seki Y, Yu X, Sekiyama T, Sato-Suzuki I, Arita H. Decreased blood serotonin in the premenstrual phase enhances negative mood in healthy women.J Psychosom Obstet Gynaecol. 2010 Jun;31(2):83-9.
  46. Cubeddu A, Giannini A, Bucci F, Merlini S, Casarosa E, Pluchino N, Luisi S, Luisi M, Genazzani AR. Paroxetine increases brain-derived neurotrophic factor in postmenopausal women. Menopause. 2010 Mar;17(2):338-43.
  47. Zitzmann M. Testosterone and the brain. Aging Male. 2006 Dec;9(4):195-9.
  48. Delhez M et al. [Testosterone and depression in men aged over 50 years. Andropause and psychopathology: minimal systemic work-up]. Ann Endocrinol (Paris). 2003 Apr;64(2):162-9.
  49. Jankowska EA, Drohomirecka A, Ponikowska B, et al. Deficiencies in circulating testosterone and dehydroepiandrosterone sulphage, and depression in men with systolic chronic heart failure. Eur J Heart Fail. 2010 Sep;12(9):966-73.
  50. Zarrouf FA, Artz S, et al. Testosterone and depression: systematic review and meta-analysis. J Psychiatr Pract 2009;15:289-305.
  51. Yehuda S et al. Essential fatty acids and the brain:from infancy to aging. Neurobiology of Aging. 2005; 26 (Suppl 1), 98–102.
  52. Faloon W. “Startling Findings About Vitamin D Levels in Life Extension® Members” Life Extension Magazine. January 2010.
  53. Hovatta I, Juhila J, Donner J. Oxidative stress in anxiety and comorbid disorders. Neurosci Res 2010; 68:261-75.
  54. Wolkowitz OM et al. Leukocyte telomere length in major depression: correlations with chronicity, inflammation and oxidative stress--preliminary findings. PLoS One. 2011a Mar 23;6(3):e17837.
  55. Kim MY et al. Leukocyte mitochondrial DNA (mtDNA) content is associated with depression in old women. Arch Gerontol Geriatr. 2011 Sep-Oct;53(2):e218-21. Epub 2010 Dec 14.
  56. Lee JW et al. Mitochondrial DNA copy number in peripheral blood is associated with cognitive function in apparently healthy elderly women. n Chim Acta. 2010 Apr 2;411(7-8):592-6. Epub 2010 Jan 28.
  57. Maes M, Mihaylova I, et al. Lower plasma coenzyme Q10 in depression: a marker for treatment resistance and chronic fatigue in depression and a risk factor to cardiovascular disorder in that illness. Neuro Endocrinol Lett 2009;30:462-9.
  58. Pettigrew JW, Levine J, et al. P-MRS study of acetyl-L-carnitine treatment in geriatric depression: preliminary results. Bipolar Disorders 2000;4:61-6.
  59. Zanardi R, Smeraldi E. A double-blind, randomised, controlled clinical trial of acetyl-L-carnitine vs. amisulpride in the treatment of dysthymia. Eur Neruopsychopharmacol 2006;16:281-7.
  60. Malaguarnera M et al. Acetyl-L-carnitine reduces depression and improves quality of life in patients with minimal hepatic encephalopathy. Scand J Gastroenterol. 2011 Jun;46(6):750-9. Epub 2011 Mar 28.
  61. Rossini M et al. Double-blind, multicenter trial comparing acetyl l-carnitine with placebo in the treatment of fibromyalgia patients. Clin Exp Rheumatol. 2007 Mar-Apr;25(2):182-8.
  62. Chowanadisai W et al. Pyrroloquinoline quinone stimulates mitochondrial biogenesis through cAMP response element-binding protein phosphorylation and increased PGC-1alpha expression. J Biol Chem. 2010 Jan 1;285(1):142-52. Epub 2009 Oct 27.
  63. Rucker R et al. Potential physiological importance of pyrroloquinoline quinone. Altern Med Rev. 2009 Sep;14(3):268-77.
  64. Tachaparian E et al. Identification of transcriptional networks responding to pyrroloquinoline quinone dietary supplementation and their influence on thioredoxin expression, and the JAK/STAT and MAPK pathways. Biochem J. 2010 Aug 1;429(3):515-26.
  65. Bauerly K et al. Altering pyrroloquinoline quinone nutritional status modulates mitochondrial, lipid, and energy metabolism in rats. PLoS One. 2011;6(7):e21779. Epub 2011 Jul 21.
  66. Zhang Y et al. Neuroprotection by pyrroloquinoline quinone (PQQ) in reversible middle cerebral artery occlusion in the adult rat. Brain Res. 2006 Jun 13;1094(1):200-6. Epub 2006 May 18.
  67. Zhang JJ et al. Protective effect of pyrroloquinoline quinone against Abeta-induced neurotoxicity in human neuroblastoma SH-SY5Y cells. Neurosci Lett. 2009 Oct 30;464(3):165-9. Epub 2009 Aug 20.
  68. Kemp DE et al. Use of insulin sensitizers for the treatment of major depressive disorder: A pilot study of pioglitazone for major depression accompanied by abdominal obesity. J Affect Disord. 2011 Jul 20. [Epub ahead of print]
  69. Ohaeri JU et al. Metabolic syndrome in severe mental disorders. Metab Syndr Relat Disord. 2011 Apr;9(2):91-8. Epub 2010 Oct 21.
  70. Tsao CW, Lin YS, et al. Cytokines and serotonin transporter in patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:899-905.
  71. Craddock D, Thomas A. Cytokines and late-life depression. Essent Psychopharmacol 2006;7:42-52.
  72. O’Brien SM, Scully P, et al. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J Psychiatr Res 2007;41:326-31.
  73. Cizza G et al. Plasma CRP levels in premenopausal women with major depression: a 12-month controlled study. Horm Metab Res. 2009 Aug;41(8):641-8. Epub 2009 Apr 30.
  74. Dantzer R et al. Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology. 2011 Apr;36(3):426-36. Epub 2010 Oct 30.
  75. Christmas DM et al. A biological pathway linking inflammation and depression: activation of indoleamine 2,3-dioxygenase. Neuropsychiatr Dis Treat. 2011;7:431-9. Epub 2011 Jul 13.
  76. Warner CH et al. Antidepressant Discontinuation Syndrome. Am Fam Physician. 2006 Aug 1;74(3):449-456.
  77. Wilson K, Mottram P. A comparison of side effects of selective serotonin reuptake inhibitors and tricyclic antidepressants in older depressed patients: A meta-analysis. Int J Geriatr Psychiatry. 2004 Aug;19(8):754–62.
  78. Schneider C, Lovett E. Depression. In: Integrative Medicine. Rakel D (ed). Saunders Elsevier, Philadelphia, pp.78, 2007.
  79. Lisanby SH et al. The effects of electroconvulsive therapy on memory of autobiographical and public events. Arch Gen Psychiatry. 2000 Jun;57(6):581-90.
  80. Calev A et al. ECT and non-memory cognition: a review. Br J Clin Psychol. 1995 Nov;34 ( Pt 4):505-15.
  81. Inoue K. [Cognitive-behavioral therapy for treatment-resistant depression]. Seishin Shinkeigaku Zasshi. 2010;112(11):1097-104.
  82. Hynninen MJ et al. A randomized controlled trial of cognitive behavioral therapy for anxiety and depression in COPD. Respir Med. 2010 Jul;104(7):986-94. Epub 2010 Mar 25.
  83. Weisz JR et al. Cognitive-behavioral therapy versus usual clinical care for youth depression: an initial test of transportability to community clinics and clinicians. J Consult Clin Psychol. 2009 Jun;77(3):383-96.
  84. Freeman MP, Fava M, et al. Complementary and Alternative Medicine in major depressive disorder: the American psychiatric association task force report. J Clin Psychiatry 2010;71:669-81.
  85. Babyak M, Blumenthal JA, et al. Exercise treatment for major depression: maintenance of therapeutic benefit at 10 months. Psychosom Med 2000;62:633-8.
  86. Hoffman BM, Babyak MA, et al. Exercise and pharmacotherapy in patients with major depression: one-year follow-up of the SMILE study. Psychosom Med 2011;73:127-33.
  87. Lam RW, Levitt AJ, et al. The Can-SAD study: a randomized controled trial of the effectiveness of light therapy and fluoxetine in patients with winter seasonal affective disorder. Am J Psychiatry 2006;163:805-12.
  88. George MS, Lisanby SH, et al. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder. Arch Gen Psychiatry 2010; 67:507-16.
  89. Schutter DJ. [Transcranial magnetic stimulation as a treatment for depression]. Tijdschr Psychiatr. 2011;53(6):343-53.
  90. McNamara RK et al. Deficits in docosahexaenoic acid and associated elevations in the metabolism of arachidonic acid and saturated fatty acids in the postmortem orbitofrontal cortex of patients with bipolar disorder. Psychiatry Res. 2008 Sep 30;160(3):285-99. Epub 2008 Aug 20.
  91. Lin, P., & Su, K. (2007). A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. Journal of Clinical Psychiatry, 68(7), 1056–1061.
  92. Tolmunen, T., Hintikka, J., Ruusunen, A., Voutilainen, S., Tanskanen, A., Valkonen, V. P., et al. (2004). Dietary folate and the risk of depression in Finnish middle-aged men. A prospective follow-up study. Psychotherapy and Psychosomatics, 73, 334–339.
  93. Sanchez-Villegas, A., Henriquez, P., Bes-Rastrollo, M., & Doreste, J. (2006). Mediterranean diet and depression. Public Health Nutrition, 9, 1104–1109.
  94. Fuller-Thomson E et al. The association between depression and thyroid disorders in a regionally representative Canadian sample. Psychol Health Med. 2011 Sep 26. [Epub ahead of print]
  95. Lojko D, Rybakowski JK. L-thyroxine augmentation of serotonergic antidepressants in female patients with refractory depression. J Affect Disord 2007;103:253-6.
  96. Fang Y et al. A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult Chinese patients with treatment-resistant major depression. J Clin Psychopharmacol. 2011 Oct;31(5):638-42.
  97. Girdler SS et al. A history of depression in women is associated with an altered GABAergic neuroactive steroid profile. Psychoneuroendocrinology. 2011 Sep 2. [Epub ahead of print]
  98. Karishma KK, Herbert J. Dehydroepiandrosterone (DHEA) stimulates neurogenesis in the hippocampus of the rat, promotes survival of newly formed neurons and prevents corticosterone-induced suppression. Eur J Neurosci. 2002 Aug;16(3):445–53.
  99. Abadie JM, Wright B et al. Effect of dehydroepiandrosterone on neurotransmitter levels and appetite regulation of the obese Zucker rat. The Obesity Research Program. Diabetes. 1993 May;42(5):662–9.
  100. Rabkin JG, McElhiney MC et al. Placebo-controlled trial of dehydroepiandrosterone (DHEA) for treatment of nonmajor depression in patients with HIV/AIDS. Am J Psychiatry. 2006 Jan;163(1):59–66.
  101. Schmidt PJ, Daly RC et al. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. Arch Gen Psychiatry. 2005 Feb;62(2):154–62.
  102. Barrett-Connor E, Von Muhlen DG et al. Bioavailable testosterone and depressed mood in older men: The Rancho Bernardo Study. J Clin Endocrinol Metab. 1999 Feb;84(2):573–7.
  103. Schweiger U, Deuschle M et al. Testosterone, gonadotropin, and cortisol secretion in male patients with major depression. Psychosom Med. 1999 May;61(3):292–6.
  104. Giltay EJ, Tishova YA, et al. Effects of testosterone supplementation on depressive syptoms and sexual dysfunction in hypogonadal men with metabolic syndrome. J Sex Med 2010;7:2572-82.
  105. Shores MM, Kivlahan DR, et al. A randomized, double-blind, placebo-controlled study of testosterone treatment in hypogonadal older men with subthreshold depression (dysthymia or minor depression). J Clin Psychiatry 2009;70:1009-16.
  106. Pope HG Jr, Cohane GH et al. Testosterone gel supplementation for men with refractory depression: A randomized, placebo-controlled trial. Am J Psychiatry. 2003 Jan;160(1):105–11.
  107. Grigoriadis S, Kennedy SH. Role of estrogen in the treatment of depression. Am J Ther. 2002 Nov;9(6):503–9.
  108. Miller KJ, Conney JC et al. Mood symptoms and cognitive performance in women estrogen users and nonusers and men. J Am Geriatr Soc. 2002 Nov;50(11):1826–30.
  109. Schneider LS, Small GW et al. Estrogen replacement therapy and antidepressant response to sertraline in older depressed women. Am J Geriatr Psychiatry. 2001;9(4):393–9.
  110. Osterlund MK. Underlying mechanisms mediating the antidepressant effects of estrogens. Biochim Biophys Acta. 2010;1800:1136-44.
  111. Joffe H, Cohen LS. Estrogen, serotonin, and mood disturbance: Where is the therapeutic bridge? Biol Psychiatry. 1998 Nov 1;44(9):798–811.
  112. Rubinow DR, Schmidt PJ et al. Estrogen-serotonin interactions: Implications for affective regulation. Biol Psychiatry. 1998 Nov 1;44(9):839–50.
  113. Bethea CL, Pecins-Thompson M et al. Ovarian steroids and serotonin neural function. Mol Neurobiol. 1998 Oct;18(2):87-123. Review.
  114. Kendall DA, Stancel GM et al. The influence of sex hormones on antidepressant-induced alterations in neurotransmitter receptor binding. J Neurosci. 1982 Mar;2(3):354–60.
  115. Barha CK and Galea LA. Influence of different estrogens on neuroplasticity and cognition in the hippocampus. Biochim Biophys Acta. 2010 Oct;1800(10):1056-67. Epub 2010 Jan 25.
  116. Vidailhet P. [Depressive recurrence: cognitive alterations and neuroplasticity]. Encephale. 2010 Dec;36 Suppl 5:S140-4.
  117. Bellipanni G, Bianchi P, et al. Effects of melatonin in perimenopausal and menopausal women: a randomized and placebo controlled study. Exp Gerontol 2001;36:297-310.
  118. Serafty MA, Osborne D, et al. A randomized double-blind placebo-controlled trial of treatment as usual plus exogenous slow-release melatonin (6mg) or placebo for sleep disturbance and depressed mood. Int Clin Psychopharmacol 2010;25:132-42.
  119. Green B. Focus on agomelatine. Curr Med Res Opin 2011;27:745-9.
  120. Hickie IB et al. Novel melatonin-based therapies: potential advances in the treatment of major depression. Lancet. 2011 Aug 13;378(9791):621-31. Epub 2011 May 17.
  121. Logan AC. Neurobehavioral aspects of omega-3 fatty acids: Possible mechanisms and therapeutic value in major depression. Altern Med Rev. 2003 Nov;8(4):410–25.
  122. Bourre JM, Dumont O et al. Essentiality of omega 3 fatty acids for brain structure and function. World Rev Nutr Diet. 1991;66:103–17.
  123. Tanskanen A, Hibbeln JR, Hintikka J, et al. Fish Consumption, Depression, and Suicidality in a General Population. Arch Gen Psychiatry. 2001;58(5):512-13.
  124. Tiemeier, H., Van Tuijl, H. R., Hofman, A., Kiliaan, A. J., & Breteler, M. M. B. (2003). Plasma fatty acid composition and depression are associated in the elderly: The Rotterdam study. American Journal of Clinical Nutrition, 78(1), 40–46.
  125. Puri BK, Counsell SJ et al. Eicosapentaenoic acid in treatment-resistant depression associated with symptom remission, structural brain changes and reduced neuronal phospholipid turnover. Int J Clin Pract. 2001 Oct;55(8):560–3.
  126. Nemets H, Nemets R et al. Omega-3 treatment of childhood depression: a controlled, double-blind pilot study. Am J Psychiatry. 2006 Jun;163(6):1098-100.
  127. Williams AL, Katz D et al. Do essential fatty acids have a role in the treatment of depression? J Affect Disord. 2006 Jul;93(1-3):117-23. Epub 2006 May 2.
  128. Burr ML, Fehily AM et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and reinfarction trial (DART). Lancet. 1989 Sep 30;2(8666):757–61.
  129. Singh RB, Niaz MA et al. Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: The Indian experiment of infarct survival—4. Cardiovasc Drugs Ther. 1997 Jul;11(3):485–91.
  130. Nadler JL, Rude RK. Disorders of magnesium metabolism. Endocrinol Metab Clin North Am 1995;24:623-41.
  131. Whittle N et al. Changes in brain protein expression are linked to magnesium restriction-induced depression-like behavior. Amino Acids. 2011 Apr;40(4):1231-48. Epub 2011 Feb 11.
  132. Eby GA, Eby KL. Magnesium for treatment-resistant depression: a review and hypothesis. Medical Hypotheses 2010;74(4):649-60.
  133. Slutsky L et al. Enhancement of learning and memory by elevating brain magnesium. Neuron. 2010 Jan 28;65(2):165-77.
  134. Abumaria N et al. Effects of elevation of brain magnesium on fear conditioning, fear extinction, and synaptic plasticity in the infralimbic prefrontal cortex and lateral amygdala. J Neurosci. 2011 Oct 19;31(42):14871-81.
  135. Hausenblas HA, Heekin K, Mutchie HL, Anton S. A systematic review of randomized controlled trials examining the effectiveness of saffron (Crocus sativus L.) on psychological and behavioral outcomes. J Integr Med. Jul 2015;13(4):231-240.
  136. Lopresti AL, Drummond PD. Saffron (Crocus sativus) for depression: a systematic review of clinical studies and examination of underlying antidepressant mechanisms of action. Human psychopharmacology. Nov 2014;29(6):517-527.
  137. Dorri SA, Hosseinzadeh H, Abnous K, Hasani FV, Robati RY, Razavi BM. Involvement of brain-derived neurotrophic factor (BDNF) on malathion induced depressive-like behavior in subacute exposure and protective effects of crocin. Iranian journal of basic medical sciences. Oct 2015;18(10):958-966.
  138. De Monte C, Carradori S, Chimenti P, et al. New insights into the biological properties of Crocus sativus L.: chemical modifications, human monoamine oxidases inhibition and molecular modeling studies. European journal of medicinal chemistry. Jul 23 2014;82:164-171.
  139. Akhondzadeh Basti A, Moshiri E, Noorbala AA, Jamshidi AH, Abbasi SH, Akhondzadeh S. Comparison of petal of Crocus sativus L. and fluoxetine in the treatment of depressed outpatients: a pilot double-blind randomized trial. Progress in neuro-psychopharmacology & biological psychiatry.Mar 30 2007;31(2):439-442.
  140. Shahmansouri N, Farokhnia M, Abbasi SH, et al. A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patients. J Affect Disord. Feb 2014;155:216-222.
  141. Talaei A, Hassanpour Moghadam M, Sajadi Tabassi SA, Mohajeri SA. Crocin, the main active saffron constituent, as an adjunctive treatment in major depressive disorder: a randomized, double-blind, placebo-controlled, pilot clinical trial. J Affect Disord. Mar 15 2015;174:51-56.
  142. Mazidi M, Shemshian M, Mousavi SH, et al. A double-blind, randomized and placebo-controlled trial of Saffron (Crocus sativus L.) in the treatment of anxiety and depression. Journal of complementary & integrative medicine. Jun 1 2016;13(2):195-199.
  143. Moshiri E, Basti AA, Noorbala AA, Jamshidi AH, Hesameddin Abbasi S, Akhondzadeh S. Crocus sativus L. (petal) in the treatment of mild-to-moderate depression: a double-blind, randomized and placebo-controlled trial. Phytomedicine: international journal of phytotherapy and phytopharmacology. Nov 2006;13(9-10):607-611.
  144. Akhondzadeh S, Tahmacebi-Pour N, Noorbala AA, Amini H, Fallah-Pour H, Jamshidi AH, Khani M. Crocus sativus L. in the treatment of mild to moderate depression: a double-blind, randomized and placebo-controlled trial. Phytotherapy research: PTR. Feb 2005;19(2):148-151.
  145. Montejo-Gonzalez AL, Llorca G, Izquierdo JA, et al. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. Journal of sex & marital therapy. Fall 1997;23(3):176-194.
  146. Kashani L, Raisi F, Saroukhani S, et al. Saffron for treatment of fluoxetine-induced sexual dysfunction in women: randomized double-blind placebo-controlled study. Hum Psycho+pharmacol. Jan 2013;28(1):54-60.
  147. Modabbernia A, Sohrabi H, Nasehi AA, et al. Effect of saffron on fluoxetine-induced sexual impairment in men: randomized double-blind placebo-controlled trial. Psychopharmacology. Oct 2012;223(4):381-388.
  148. Marjoribanks J, Brown J, O'Brien PM, Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. The Cochrane database of systematic reviews.2013;6:Cd001396.
  149. Agha-Hosseini M, Kashani L, Aleyaseen A, Ghoreishi A, Rahmanpour H, Zarrinara AR, Akhondzadeh S. Crocus sativus L. (saffron) in the treatment of premenstrual syndrome: a double-blind, randomised and placebo-controlled trial. BJOG: an international journal of obstetrics and gynaecology. Mar 2008;115(4):515-519.
  150. Murphy SE, Longhitano C et al. Tryptophan supplementation induces a positive bias in the processing of emotional material in healthy female volunteers. Psychopharmacology (Berl). 2006 Jul;187(1):121–30.
  151. Kaye WH et al. Effects of acute tryptophan depletion on mood in bulimia nervosa. Biol Psychiatry. 2000 Jan 15;47(2):151-7.
  152. Booij L, Swenne CA, et al. Tryptophan depletion affects heart rate variability and impulsivity in remitted depressed patients with a history of suicidal ideation. Biol Psychiatry 2006;60:507-14.
  153. Neumeister A, Turner EH, et al. Effects of tryptophan depletion vs. catecholamine depletion in patients with seasonal affective disorder in remission with light therapy. Arch Gen Psychiatry 1998;55:524-30.
  154. Papakostas GI, Mishoulon D, et al. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind randomized clinical trial. Am J Psychiatry 2010; 167:942-8.
  155. Alpert JE, Papakostas G, et al. S-adenosyl-methionine (SAMe) as an adjunct for reistant major depressive disorder. J of Clin Psycopharmacol 2004;24:661-4.
  156. Alpert, J. E., Mischoulon, D., Nierenberg, A. A., & Fava, M. (2000). Nutrition and depression: Focus on folate. Nutrition, 16, 544–546.
  157. Fava M et al. Folate, vitamin B12, and homocysteine in major depressive disorder. American Journal of Psychiatry, 1997 Mar;154(3), 426–428.
  158. Coppen A, Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: A randomised, placebo controlled trial. J Affect Disord. 2000 Nov;60(2):121–30.
  159. Morris MS, Fava M et al. Depression and folate status in the US population. Psychother Psychosom. 2003 Mar;72(2):80–7.
  160. Willems FF et al. Pharmacokinetic study on the utilisation of 5-methyltetrahydrofolate and folic acid in patients with coronary artery disease. Br J Pharmacol. 2004 Mar;141(5):825-30. Epub 2004 Feb 9.
  161. Lewis SJ et al. The thermolabile variant of MTHFR is associated with depression in the British Women's Heart and Health Study and a meta-analysis. Mol Psychiatry. 2006 Apr;11(4):352-60.
  162. Hector, M., & Burton, J. R. (1988). What are the psychiatric manifestations of vitamin B12 deficiency? Journal of the American Geriatrics Society, 36(12), 1105–1112.
  163. Sun, Y., Lai, M., & Lu, C. (2005). Effectiveness of vitamin B12 on diabetic neuropathy: Systematic review of clinical controlled trials. Acta Neurologica Taiwanica, 14(2), 48–54.
  164. Bertoglio K, James JS, et al. Pilot study of the effect of methyl B12 treatment on behavioral and biomarker measures in children with autism. J Altern Complement Med 2010;16:555-60.
  165. Baldewicz, T. T., Goodkin, K., Blaney, N. T., Shor-Posner, G., Kumar, M., Wilkie, F. L., et al. (2000). Cobalamin level is related to self-reported and clinically rated mood and to syndromal depression in bereaved HIV-1+ and HIV-1- homosexual men. Journal of Psychosomatic Research, 48(2), 177–185.
  166. Adams PW, Rose DP, et al. Effect of pyridoxine hydrochloride (vitamin B6) upon depression associated with oral contraceptives. Lancet 1973;1:897-904.
  167. Merete C et al. Vitamin B6 is associated with depressive symptomatology in Massachusetts elders. J Am Coll Nutr. 2008 Jun;27(3):421-7.
  168. Lucas M et al. Coffee, caffeine, and risk of depression among women. Arch Intern Med. 2011 Sep 26;171(17):1571-8.
  169. Ruusunen A et al. Coffee, tea and caffeine intake and the risk of severe depression in middle-aged Finnish men: the Kuopio Ischaemic Heart Disease Risk Factor Study. Public Health Nutr. 2010 Aug;13(8):1215-20. Epub 2010 Apr 1.
  170. Tunnicliffe JM et al. Chlorogenic acid differentially affects postprandial glucose and glucose-dependent insulinotropic polypeptide response in rats. Appl Physiol Nutr Metab. 2011 Oct;36(5):650-9. Epub 2011 Oct 6.
  171. Zhang LT et al. [Effect of chlorogenic acid on disordered glucose and lipid metabolism in db/db mice and its mechanism]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2011 Jun;33(3):281-6.
  172. Thom E. The effect of chlorogenic acid enriched coffee on glucose absorption in healthy volunteers and its effect on body mass when used long-term in overweight and obese people. J Int Med Res. 2007 Nov-Dec;35(6):900-8.
  173. McCarty MF et al. Enhancing central and peripheral insulin activity as a strategy for the treatment of endogenous depression--an adjuvant role for chromium picolinate? Med Hypotheses. 1994 Oct;43(4):247-52.
  174. MacLeod MN, Gaynes BN, et al. Chromium potentiation of antidepressant pharmacotherapy for dysthymic disorder in 5 patients. J Clin Psychiatry1999;60:237-40.
  175. Davidson JR, Abraham K, et al. Efectiveness ofchromium in atypical depression. Biol Psychiatry 2003;53:261-4.
  176. Docherty JP, Sack DA, et al. A double-blind, placebo controlled, exploratory trial of chromium picolinate inatypical depression: effect on carbohydrate craving. 2005;11:302-14.
  177. Berk M, Dean O, et al. The efficacy of N-acetycysteine as an adjunctive treatment in bipolar depression: an open label trial. J Afect Disord 2011;Jun 28[Epub ahead of print].
  178. Jin HY, Joung SJ, et al. The effect of alpha-lipoic acid on sumptoms and skin blood flow in diabetic neuropathy. Diabet Med 2007;24:1034-8.
  179. Hawkes WC, Hornbostel L. Effects of dietary selenium on mood in healthy men living in a metabolic research unit. Biol Psychiatry 1996;39:121-8.
  180. Pathak L, Agrawal Y, Dhir A. Natural polyphenols in the management of major depression. Expert opinion on investigational drugs. Jul 2013;22(7):863-880.
  181. Lopresti AL, Hood SD, Drummond PD. Multiple antidepressant potential modes of action of curcumin: a review of its anti-inflammatory, monoaminergic, antioxidant, immune-modulating and neuroprotective effects. Journal of psychopharmacology (Oxford, England). Dec 2012;26(12):1512-1524.
  182. Zhang L, Luo J, Zhang M, Yao W, Ma X, Yu SY. Effects of curcumin on chronic, unpredictable, mild, stress-induced depressive-like behaviour and structural plasticity in the lateral amygdala of rats. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP). Jan 9 2014:1-14.
  183. Zhao X, Wang C, Zhang JF, Liu L, Liu AM, Ma Q, . . . Xu Y. Chronic curcumin treatment normalizes depression-like behaviors in mice with mononeuropathy: involvement of supraspinal serotonergic system and GABA receptor. Psychopharmacology. Dec 3 2013.
  184. Finan PH, Smith MT. The comorbidity of insomnia, chronic pain, and depression: dopamine as a putative mechanism. Sleep medicine reviews. Jun 2013;17(3):173-183.
  185. Ong KS, Keng SB. The biological, social, and psychological relationship between depression and chronic pain. Cranio : the journal of craniomandibular practice. Oct 2003;21(4):286-294.
  186. Arora V, Kuhad A, Tiwari V, Chopra K. Curcumin ameliorates reserpine-induced pain-depression dyad: behavioural, biochemical, neurochemical and molecular evidences. Psychoneuroendocrinology. Nov 2011;36(10):1570-1581.
  187. Jiang H, Wang Z, Wang Y, Xie K, Zhang Q, Luan Q, . . . Liu D. Antidepressant-like effects of curcumin in chronic mild stress of rats: involvement of its anti-inflammatory action. Progress in neuro-psychopharmacology & biological psychiatry. Dec 2 2013;47:33-39.
  188. Bergman J, Miodownik C, Bersudsky Y, Sokolik S, Lerner PP, Kreinin A, . . . Lerner V. Curcumin as an add-on to antidepressive treatment: a randomized, double-blind, placebo-controlled, pilot clinical study. Clinical neuropharmacology. May-Jun 2013;36(3):73-77.
  189. Gupta SC, Kismali G, Aggarwal BB. Curcumin, a component of turmeric: from farm to pharmacy. BioFactors (Oxford, England). Jan-Feb 2013;39(1):2-13.
  190. Noorafshan A, Ashkani-Esfahani S. A review of therapeutic effects of curcumin. Current pharmaceutical design. 2013;19(11):2032-2046.
  191. Whiskey E, Taylor D. A review of the adverse effects and safety of noradrenergic antidepressants. Journal of psychopharmacology (Oxford, England). Aug 2013;27(8):732-739.
  192. Henry A, Kisicki MD, Varley C. Efficacy and safety of antidepressant drug treatment in children and adolescents. Molecular psychiatry. Dec 2012;17(12):1186-1193.
  193. Asher GN, Spelman K. Clinical utility of curcumin extract. Alternative therapies in health and medicine. Mar-Apr 2013;19(2):20-22.
  194. Nangia M, Syed W et al. Efficacy and safety of St. John’s wort for the treatment of major depression. Public Health Nutr. 2000 Dec;3(4A):487–94.
  195. Lecrubier Y, Clerc G, Didi R, et al. Efficacy of St. John’s wort extract WS 5770 in major depression: a double-blind, placebo-controlled trial. Am J Psychiatry. 2002 Aug;159(8):1361-6.
  196. Schrader E. Equivalence of St John’s wort extract (Ze 117) and fluoxitine: a randomized controlled study in mild-moderate depression. Int Clin Psychopharmacol 2000:15:61-8.
  197. Szegedi A, Kohnen R et al. Acute treatment of moderate to severe depression with Hypericum extract WE 5570 (St John’s wort): Randomized controlled double-blind non-inferiority trial versus paroxetine. BMJ 2005;330:503.
  198. Butterweck V. Mechanism of action of St John’s wort in depression: what is known? CNS Drugs 2003;17:539-62.
  199. Can OD et al. Effects of Insulin and St. John's Wort Treatments on Anxiety, Locomotory Activity, Depression, and Active Learning Parameters of Streptozotocin-Diabetic Rats. Planta Med. 2011 Aug 19. [Epub ahead of print]
  200. Kim HL, Streltzer J et al. St. John’s wort for depression: A meta-analysis of well-defined clinical trials. J Nerv Ment Dis. 1999 Sep;187(9):532–8.
  201. Linde K, Ramirez G et al. St John’s wort for depression: An overview and meta-analysis of randomised clinical trials. BMJ. 1996 Aug 3;313(7052):253–8.
  202. Namri A, Mizoue T, et al. Association between serum 25-hydroxyvitamin D and depressive symptoms in Japanese: analysis by survey season. Eur J Clin Nutr 2009;63:1444-7.
  203. Shipowick CK, Moore CB, et al. Vitamin D and depressive symptoms in women during the winter: a pilot study. Appl Nurs Res 2009;22:221-5.
  204. May HT, Bair TL, et al. Association of vitamin D levels with incident depression among a general cardiovascular population. Am Heart J 2010;159:1037-43.
  205. Jorde R, Sneve M, et al. Effects of vitamin D supplementation on symptoms of depression in overweight and obese subjects: randomized double blind trial. J Intern Med 2008;264:599-609.
  206. Nowak G, Szewczyk B. Mechanisms contributing to antidepressant zinc actions. Pol J Pharmacol. 2002 Nov;54(6):587–92.
  207. Levenson CW. Zinc: the new antidepressant? Nutrition Reviews 2006;64:39-42.
  208. Maes M, D’Haese PC et al. Hypozincemia in depression. J Affect Disord. 1994 Jun;31(2):135–40.
  209. Maes M, Vandoolaeghe E et al. Lower serum zinc in major depression is a sensitive marker of treatment resistance and of the immune/inflammatory response in that illness. Biol Psychiatry. 1997 Sep 1;42(5):349–58.
  210. McLoughlin IJ, Hodge JS. Zinc in depressive disorder. Acta Psychiatr Scand. 1990 Dec;82(6):451–3.
  211. Nowak G, Schlegel-Zawadzka M. Alterations in serum and brain trace element levels after antidepressant treatment: Part I. Zinc. Biol Trace Elem Res. 1999 Jan;67(1):85–92.
  212. Nowak G, Siwek M, et al. Effect of zinc supplementation on antidepressant therapy in unipolar depression: a preliminary placebo-contolled study. Pol J Pharmacol 2003;55:1143-7.
  213. Kroczka B, Branski P et al. Antidepressant-like properties of zinc in rodent forced swim test. Brain Res Bull. 2001 May 15;55(2):297–300.
  214. Sairanen M, Lucas G, et al. Brain-derived neurotrophic factor and antidepressant drugs have different but coordinated effects on neuronal turnover, proliferation and survival in the adult dentate gyrus. J Neurosci 2005;25:1089-94.
  215. Levine J, Barak Y et al. Double blind controlled trial of inositol treatment of depression. Am J Psychiatry 1995;152:1084-6.
  216. Chengappa KN, Levine J, et al. Inositol as an add-on treatment for bipolar depression. Bipolar Disord 2000;2:46-55.
  217. Evins, A. E., Demopulos, C., Yovel, I., Culhane, M., Ogutha, J., Grandin, L. D., et al. (2006). Inositol augmentation of lithium or valproate for bipolar depression. Bipolar Disorders, 8, 168–174.
  218. Petra AI, Panagiotidou S, Hatziagelaki E, Stewart JM, Conti P, Theoharides TC. Gut-Microbiota-Brain Axis and Its Effect on Neuropsychiatric Disorders With Suspected Immune Dysregulation. Clinical therapeutics.May 1 2015;37(5):984-995.
  219. Foster JA, Lyte M, Meyer E, Cryan JF. Gut microbiota and brain function: An evolving field in neuroscience. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP).Oct 4 2015.
  220. Forsythe P, Sudo N, Dinan T, Taylor VH, Bienenstock J. Mood and gut feelings. Brain Behav Immun.Jan 2010;24(1):9-16.
  221. Forsythe P, Kunze WA. Voices from within: gut microbes and the CNS. Cellular and molecular life sciences: CMLS.Jan 2013;70(1):55-69.
  222. Dinan TG, Cryan JF. Regulation of the stress response by the gut microbiota: implications for psychoneuroendocrinology. Psychoneuroendocrinology.Sep 2012;37(9):1369-1378.
  223. Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci.2012;13(10):701-712.
  224. Sanders ME. Probiotics: Definition, Sources, Selection, and Uses. Clinical Infectious Diseases.February 1, 2008 2008;46(Supplement 2):S58-S61.
  225. Bravo JA, Forsythe P, Chew MV, et al. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proceedings of the National Academy of Sciences of the United States of America. Sep 20 2011;108(38):16050-16055.
  226. Gareau MG, Jury J, MacQueen G, Sherman PM, Perdue MH. Probiotic treatment of rat pups normalises corticosterone release and ameliorates colonic dysfunction induced by maternal separation. Gut.Nov 2007;56(11):1522-1528.
  227. Messaoudi M, Lalonde R, Violle N, et al. Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects. The British journal of nutrition. Mar 2011;105(5):755-764.
  228. Arseneault-Breard J, Rondeau I, Gilbert K, Girard SA, Tompkins TA, Godbout R, Rousseau G. Combination of Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 reduces post-myocardial infarction depression symptoms and restores intestinal permeability in a rat model. The British journal of nutrition.Jun 2012;107(12):1793-1799.
  229. Messaoudi M, Violle N, Bisson JF, Desor D, Javelot H, Rougeot C. Beneficial psychological effects of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in healthy human volunteers. Gut Microbes. Jul-Aug 2011;2(4):256-261.
  230. Calcaterra NE, Barrow JC. Classics in chemical neuroscience: diazepam (valium). ACS chemical neuroscience.Apr 16 2014;5(4):253-260.